Daiichi Sankyo, Inc.

← The SEC Ephemeris: the whole map

Daiichi Sankyo, Inc. this action below

In the graph: all 2 documents (4 pages).

Application: BLA 761366
Ticker: Daiichi Sankyo, Inc.
Product: this action below
Disease area: Not yet classified
Response path: Not yet classified
Complete Response Letters: June 26, 2024 · August 24, 2018

From FDA letters and SEC filings. Not investment or medical advice.

Not yet classified

CellTrans Inc. Donislecel manufactured at your Chicago
CELLTRION, Inc. Steqeyma
Checkpoint Therapeutics, Incorporated cosibelimab
Chelsea Therapeutics, Inc. NORTHERA
Chemo Research, S.L. dienogest
Chiesi USA, Inc. PRX-102
Cingulate Therapeutics, LLC dexmethylphenidate hydrochloride
Cipla USA, Inc.
Citius Pharmaceuticals, Inc. Lymphir
Clarus Therapeutics, Inc. testosterone undecanoate
CLASS 2 RESUBMISSION Romidepsin
Clearside Biomedical, Inc. XIPERE
CMP Development LLC sildenafil
Coherus BioSciences, Inc. toripalimab-tpzi
Conjupro Biotherapeutics Inc. irinotecan liposome
CooperSurgical, Inc. Paragard
Corium, Inc. ADLARITY
CorMedix Inc. taurolidine
CSL Behring LLC CSL312
Cyclomedica Australia Pty Ltd. Technegas™ Technetium Tc-99m carbon aerosol
Daiichi Sankyo, Inc. this action below
DBV Technologies S.A. Peanut Allergen Extract manufactured at your location
Defender Pharmaceuticals, Inc scopolamine
Delcath Systems, Incorporated Melblez
Disc Medicine, Inc. bitopertin
Dow Pharmaceutical Sciences, Inc. halobetasol propionate
Dr. Reddy’s Laboratories, Inc. AVT03
DURECT Corporation POSIMIR
Eagle Pharmaceuticals, Inc. Fulvestrant
ELC Group Lutrate®
Elevar Therapeutics, Inc. rivoceranib
Eli Lilly and Company lebrikizumab
EMD Serono, Inc. cladribine
Emory Partners, LLC Dyanavel XR
Esteve Pharmaceuticals, S.A. celecoxib
Evergreen Theragnostics, Inc.
Evofem, Inc. Amphora
Evoke Pharma, Inc. Gimoti
Evolus, Inc. otulinum toxin Type A
Eyenovia, Inc. MYDCOMBI

All 283 on the full map →

Group by

Build queue · replay at pipeline speed